Core Viewpoint - The analysis indicates a positive outlook for AngioDynamics, Inc. (NASDAQ: ANGO) based on its growing portfolio of medical technology products [1] Company Summary - AngioDynamics is recognized for its focus on medical technology, particularly in the small- to mid-cap sector, which is often overlooked by investors [1] - The company has been rated a Buy, suggesting confidence in its growth potential and market position [1] Industry Context - The analysis occasionally includes insights on large-cap companies to provide a broader perspective on equity markets, indicating a comprehensive approach to market research [1]

Core Insights - AngioDynamics, Inc. (ANGO) experienced an 8.08% increase in stock price, reaching $11.97, following the announcement of a narrower quarterly loss and revenue exceeding expectations in the first quarter [1] Financial Performance - The company reported a net loss of $10.9 million, or $0.26 per share, which is an improvement from a loss of $12.8 million, or $0.31 per share, in the same quarter last year [1] - Revenue increased by 12.2%, amounting to $75.7 million compared to $67.5 million a year ago [1] Stock Market Activity - Shares traded within a range of $11.35 to $12.76, compared to a previous close of $11.07 on the Nasdaq [2] - Trading volume surged to 1.99 million shares, significantly higher than the average volume of 534,634 shares [2] - The stock is currently within its 52-week range of $5.83 to $13.50 [2]

Core Viewpoint - AngioDynamics reported a smaller-than-expected loss in Q1 2026, leading to a 10.5% increase in stock price, despite ongoing challenges in achieving profitability [1][3][6]. Financial Performance - Analysts had anticipated a loss of $0.12 per share, but AngioDynamics reported a loss of $0.10 per share, with sales reaching $75.7 million, exceeding the forecast of $72.7 million [1][3]. - Year-over-year sales growth was 12%, driven by a 26% increase in the med tech segment, while the medical devices segment only grew by 2% [3]. - Gross profit margins improved to 55.3%, a 90 basis point increase from the previous year, but GAAP losses were significantly worse at $0.26 per share [3][4]. Future Guidance - The company expects sales for the fiscal year to be between $308 million and $313 million, with med tech sales projected to grow in the mid-teens, while medical devices are expected to remain flat [5]. - Adjusted profits are anticipated to remain negative throughout the year, with estimates ranging from a loss of $0.23 to $0.33 per share [5]. - Free cash flow is expected to be positive, but specific figures were not provided [5]. Investment Considerations - Despite the stock price surge, the company is still years away from achieving profitability, suggesting that investors may want to consider selling their shares [6]. - AngioDynamics was not included in a list of recommended stocks by analysts, indicating a cautious outlook for potential investors [9].

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points, the Dow up 0.15% to 46,510.40, the NASDAQ rising 0.47% to 22,861.86, and the S&P 500 increasing 0.27% to 6,729.47 [1] - Information technology shares increased by 0.9%, while real estate stocks fell by 0.6% [1] Company Earnings - AngioDynamics, Inc. reported better-than-expected earnings for Q1, with losses of 10 cents per share, beating the analyst consensus estimate of 12 cents per share. Quarterly sales were $75.711 million, exceeding the consensus estimate of $72.725 million [2] - The company raised its FY26 adjusted EPS and sales guidance [2] Commodity Prices - Oil traded down 1% to $61.20, while gold rose 0.5% to $3,916.00. Silver increased by 0.4% to $47.875, and copper rose 1.1% to $4.9375 [5] Global Market Performance - European shares were higher, with the eurozone's STOXX 600 gaining 0.7%, Spain's IBEX 35 up 0.1%, London's FTSE 100 down 0.1%, Germany's DAX 40 up 1.4%, and France's CAC 40 rising 1.4% [6] - Asian markets closed higher, with Japan's Nikkei 225 gaining 0.87% and Hong Kong's Hang Seng index up 1.61% [7] Stock Movements - Aspire Biopharma Holdings Inc shares surged 81% to $0.39 after announcing a milestone roadmap for FDA submission [9] - Concorde International Group Ltd shares increased by 41% to $3.64, while Iveda Solutions Inc shares rose 39% to $1.89 [9] - Uni-Fuels Holdings Ltd shares dropped 71% to $1.46, and Nvni Group Ltd shares fell 53% to $0.35 following a reverse stock split announcement [9] - FlexShopper Inc shares decreased by 45% to $0.31 after the resignation of its Director due to financial matters [9] Employment Data - U.S.-based employers announced 54,064 job cuts in September, a decrease from 85,979 in August [10]

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points, the Dow up 0.15% to 46,510.40, the NASDAQ rising 0.47% to 22,861.86, and the S&P 500 increasing 0.27% to 6,729.47 [1] - Information technology shares increased by 0.9%, while real estate stocks fell by 0.6% [1] Company Earnings - AngioDynamics, Inc. reported better-than-expected earnings for Q1, with losses of 10 cents per share, beating the analyst consensus estimate of 12 cents per share. Quarterly sales were $75.711 million, exceeding the consensus estimate of $72.725 million. The company raised its FY26 adjusted EPS and sales guidance [2] Commodity Prices - Oil traded down 1% to $61.20, while gold rose 0.5% to $3,916.00. Silver increased by 0.4% to $47.875, and copper rose 1.1% to $4.9375 [5] European Market Performance - European shares were higher, with the eurozone's STOXX 600 gaining 0.7%, Spain's IBEX 35 Index up 0.1%, London's FTSE 100 down 0.1%, Germany's DAX 40 gaining 1.4%, and France's CAC 40 rising 1.4% [6] Asian Market Performance - Asian markets closed higher, with Japan's Nikkei 225 gaining 0.87% and Hong Kong's Hang Seng index increasing by 1.61% [7] Stock Movements - Aspire Biopharma Holdings Inc shares surged 81% to $0.39 after announcing a milestone roadmap for FDA submission. Concorde International Group Ltd shares rose 41% to $3.64, and Iveda Solutions Inc shares increased by 39% to $1.89. Conversely, Uni-Fuels Holdings Ltd shares dropped 71% to $1.46, and Nvni Group Ltd shares fell 53% to $0.35 following a reverse stock split announcement. FlexShopper Inc shares decreased by 45% to $0.31 after the resignation of its Director due to financial matters [9]

Market Overview - U.S. stock futures are mixed as investors react to the ongoing government shutdown, while technology shares rally, providing support [1][2] - Nasdaq 100 futures are leading with gains of approximately 0.36% to 0.5%, driven by positive sentiment in the semiconductor sector [2] - S&P 500 futures are up around 0.17% to 0.2%, indicating a modest risk appetite, while Dow Jones futures are slightly down by 0.02% to 0.1% [2] Major Market Indexes - The S&P 500 closed at a record high of 6,711.20, up approximately 0.3%, while the Nasdaq Composite gained 0.4% to reach 22,755.16 [3] - The Dow Jones Industrial Average also set a record high at 46,441.10, increasing by 0.1% [3] - Goldman Sachs raised its S&P 500 projection to 6,800, citing strong performance from major U.S. companies [3] Upcoming Market Events - The government shutdown is causing delays in key economic data releases, including the jobs report and weekly jobless claims [4] - A Challenger Job Cuts report indicated a 37% drop in September job cuts from August, which may influence rate-cut expectations [4] - The third-quarter earnings season is set to begin in mid-October, with analysts forecasting a 7.9% year-over-year earnings growth for S&P 500 companies [5] Major Stock News and Corporate Developments - The semiconductor sector is experiencing a rally, with shares of Advanced Micro Devices (AMD) up about 3%, Broadcom (AVGO) up 2%, and Nvidia (NVDA) gaining approximately 1.5% [6] - Tesla (TSLA) shares are up nearly 2% ahead of its third-quarter delivery figures [7] - Stellantis (STLA) reported a 6% rise in U.S. sales, leading to a stock increase of up to 7% in overseas trading [8] Corporate Earnings News - Conagra Brands (CAG) shares jumped 5.4% after reporting first-quarter fiscal 2026 adjusted earnings that exceeded estimates [9] - Nike (NKE) saw a significant rise of 6.4% after its first-quarter fiscal 2026 revenues beat expectations [9] - Corteva, Inc. (CTVA) shares fell 9.1% after announcing plans to split its seed and crop-protection businesses [9] Broader Market Trends - Gold futures are rising, hovering near a record at $3,910 an ounce, reflecting its status as a safe-haven asset [11] - Bitcoin advanced 1% to approximately $118,800, reaching its highest level since mid-August [11] - The 10-year Treasury yield slipped slightly, trading between 4.09% and 4.11% [11]

Financial Data and Key Metrics Changes - Revenue increased by 12.2% to $75.7 million, driven by growth across both med-tech and med-device segments [12][21] - Gross margin for Q1 FY26 was 55.3%, a 90 basis point increase from the previous year [16] - Adjusted net loss for Q1 FY26 was $4.2 million, an improvement from a loss of $4.4 million in the same quarter last year [18] Business Line Data and Key Metrics Changes - Med-tech revenue was $35.3 million, a 26.1% increase, while med-device revenue was $40.4 million, an increase of 2.3% [13] - Auryon platform contributed $16.5 million in revenue, growing 20.1% year-over-year [14] - Mechanical thrombectomy revenue increased by 41.2% year-over-year, with AngioVac revenue at $8 million (37.1% increase) and AlphaVac revenue at $3.3 million (52.3% increase) [15] Market Data and Key Metrics Changes - Med-tech platforms comprised 47% of total revenue, up from 41% a year ago, illustrating the strategic shift towards med-tech [13] - International adoption of Auryon following CE mark approval contributed approximately $500,000 in revenue during the quarter [14] Company Strategy and Development Direction - The company is focused on expanding its product portfolio to compete in large, fast-growing markets, particularly in med-tech [5] - Continued investment in Auryon and plans to enter the coronary market are part of the long-term growth strategy [6] - The company aims to increase its market share in the hospital segment, driving both top-line growth and higher margins [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the med-tech segment, particularly in mechanical thrombectomy and NanoKnife [26] - The company expects to be cash flow positive for the current fiscal year, with significant cash generation anticipated in Q4 [20] - Guidance for FY26 was raised, expecting net sales in the range of $308 to $313 million, reflecting growth of 5% to 7% over the previous year [21] Other Important Information - The company continues to face tariff expenses, with an estimated impact of $4 to $6 million for the full fiscal year [17] - R&D expenses were $6.4 million, or 8.5% of sales, as the company remains committed to investing in long-term growth initiatives [18] Q&A Session Summary Question: Guidance on growth drivers - The increase in guidance is primarily driven by mechanical thrombectomy and NanoKnife segments, with expectations for continued solid contributions from Auryon [26] Question: NanoKnife disposable revenue specifics - The growth in NanoKnife disposable revenue is largely driven by prostate initiatives, with no significant one-time stocking effects noted [30] Question: Update on mechanical thrombectomy hospital penetration - There has been good uptake in hospitals, with ongoing efforts to convert accounts into value analysis committee approvals [33] Question: Sales force updates in mechanical thrombectomy - The sales force for mechanical thrombectomy has increased to 50 dedicated reps, with plans for further investments in the NanoKnife urology sales force [38] Question: Revenue growth attribution to price increases - Revenue growth in mechanical thrombectomy is attributed to a combination of price increases, new customer acquisitions, and increased utilization [42] Question: Update on ongoing clinical trials - The Ambition BTK study is progressing well, with positive expectations for Auryon's role in atherectomy treatments [44]

Financial Data and Key Metrics Changes - Revenue increased by 12.2% to $75.7 million, driven by growth across both med-tech and med-device segments [12][21] - Gross margin for Q1 FY26 was 55.3%, a 90 basis point increase from the previous year [16] - Adjusted net loss for Q1 FY26 was $4.2 million, improving from a loss of $4.4 million in the same quarter last year [18] Business Line Data and Key Metrics Changes - Med-tech revenue was $35.3 million, a 26.1% increase, while med-device revenue was $40.4 million, an increase of 2.3% [13] - Auryon platform contributed $16.5 million in revenue, growing 20.1% year-over-year [14] - Mechanical thrombectomy revenue increased by 41.2% year-over-year, with AngioVac revenue at $8 million (37.1% increase) and AlphaVac revenue at $3.3 million (52.3% increase) [15] Market Data and Key Metrics Changes - Med-tech platforms comprised 47% of total revenue, up from 41% a year ago, illustrating the strategic shift towards med-tech [13] - International adoption of Auryon following CE mark approval contributed approximately $500,000 in revenue [14] Company Strategy and Development Direction - The company is focused on expanding its product portfolio into large, fast-growing markets, particularly in med-tech [5] - Continued investment in Auryon and mechanical thrombectomy products is expected to drive long-term growth [6][10] - The company aims to increase its market share and expand access to new opportunities, particularly in the hospital market [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the med-tech segment, particularly Auryon and NanoKnife, as key drivers for future revenue [21][27] - The company anticipates continued strong performance in mechanical thrombectomy and NanoKnife, with expectations for growth in the urology market [27][28] Other Important Information - The company expects to incur between $4 million and $6 million in tariff expenses for the full fiscal year 2026 [17] - Cash utilization was better than expected, with a cash balance of $38.8 million at the end of Q1 FY26 [20] Q&A Session Summary Question: Guidance on growth drivers - The increase in guidance is primarily driven by mechanical thrombectomy and NanoKnife segments, with expectations for continued solid contributions from Auryon [25][26] Question: NanoKnife disposable revenue specifics - The strong growth in NanoKnife disposable revenue is largely driven by prostate initiatives, with no significant one-time stocking effects noted [29][30] Question: Update on mechanical thrombectomy hospital penetration - There has been good uptake in hospitals, with ongoing efforts to convert interest into approvals for product usage [32][33] Question: Sales force updates - The company has increased its sales force for mechanical thrombectomy by 25%, now totaling 50 dedicated sales reps [37][38] Question: Revenue growth attribution - Revenue growth in mechanical thrombectomy is attributed to a combination of price increases, new customer acquisitions, and increased utilization [41][42] Question: Clinical trials update - The Ambition BTK study is progressing well, with positive expectations for its impact on the Auryon business [43][44]

Financial Data and Key Metrics Changes - Revenue increased by 12.2% to $75.7 million, driven by growth across both med-tech and med-device segments [12][21] - Gross margin for Q1 FY26 was 55.3%, a 90 basis point increase from the previous year [17] - Adjusted net loss for Q1 FY26 was $4.2 million, improving from a loss of $4.4 million in the same quarter last year [19] Business Line Data and Key Metrics Changes - Med-tech revenue was $35.3 million, a 26.1% increase, while med-device revenue was $40.4 million, an increase of 2.3% [13] - Auryon platform contributed $16.5 million in revenue, growing 20.1% year-over-year [15] - Mechanical thrombectomy revenue increased by 41.2% year-over-year, with AngioVac revenue at $8 million (37.1% increase) and AlphaVac revenue at $3.3 million (52.3% increase) [16] Market Data and Key Metrics Changes - Med-tech platforms comprised 47% of total revenue, up from 41% a year ago, illustrating the strategy to increase revenue from this segment [14] - The annual revenue of the med-tech segment grew from $41 million in 2020 to $127 million in 2025, representing a compound annual growth rate of 25% [15] Company Strategy and Development Direction - The company is focused on growing its med-tech segment, particularly through innovative products like Auryon and NanoKnife, which are expected to drive future growth [5][7] - Continued investment in R&D initiatives is planned to support long-term growth, targeting approximately 10% of sales [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the med-tech segment, particularly in mechanical thrombectomy and NanoKnife, with expectations for continued strong performance [26][27] - The company anticipates being cash flow positive for the current fiscal year, with significant cash generation expected in Q4 [20] Other Important Information - The company expects net sales for FY26 to be in the range of $308 to $313 million, an increase from previous guidance [21] - Tariff expenses for FY26 are estimated to be between $4 and $6 million [18] Q&A Session Summary Question: Guidance on growth drivers - The increase in guidance is primarily driven by mechanical thrombectomy and NanoKnife segments, with expectations for continued growth in these areas [25][26] Question: Update on mechanical thrombectomy hospital penetration - There has been good uptake in hospitals, with ongoing efforts to convert accounts into value analysis committee approvals [31][32] Question: Revenue growth attributable to price increases - Revenue growth is driven by a combination of price increases, new customer acquisitions, and increased utilization [38][39] Question: Update on clinical trials for Ambition BTK - The Ambition BTK study is progressing well, with enrollment in both RCT and registry segments, expected to significantly impact the Auryon business [40][41]